IDEXX Laboratories, Inc. IDXX

Full chart Compare
Set alert

Price alert · IDXX

All alert types
698.55 USD +26.51 (+3.94%)

At closeNov 4, 2026, 4:20 PM EST

698.55 0.00 0.00%

After hours · Nov 4, 4:20 PM ET

681.70 Day range 713.74
500.61 52-week range 769.98
YTD
+3.25%
1 year
-3.26%
Market cap
55.04B
Revenue (ttm)
4.66B
Profit margin
25.36%
EPS (ttm)
14.84
Shares out
78.79M
P/E ratio
47.07
Forward P/E
41.52
YTD return
+3.25%
1-year return
-3.26%
Volume
1.40M
Avg volume
558.69K
Open
686.23
Previous close
672.04
Day's range
681.70 – 713.74
52-week range
500.61 – 769.98
Beta
1.54
Analysts
Buy
Price target
708.83 (+1.5%)
Earnings date
Feb 1, 2027

3M +113.77 (+19.46%)

500600700Aug 13Sep 1Sep 21Oct 8Oct 27698.55

Key statistics

Enterprise value
53.72B
PEG ratio
3.68
Price / sales
11.80
Price / book
29.46
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
9.90%
Free cash flow
1.06B
Total cash
197.54M
Total debt
972.96M
Return on equity
68.93%
Short % of float
2.80%
50-day average
538.81
200-day average
572.20

Financials — quick view

All financials
IDXX Revenue — quarterly 1.22B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
IDXX Net income — quarterly 338.41M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
IDXX EPS — quarterly 4.29
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

IDXX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 1, 2027Dec 30, 20263.36———
Nov 2, 2026Sep 30, 20263.733.96+0.23+6.17%
Aug 4, 2026Jun 30, 20263.944.27+0.33+8.38%
May 5, 2026Mar 31, 20263.413.47+0.06+1.76%
Feb 2, 2026Dec 31, 20252.933.08+0.15+5.12%
Nov 3, 2025Sep 30, 20253.143.40+0.26+8.28%

Upgrades / downgrades

IDXX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 3, 2026Morgan StanleymainOverweightOverweight
Nov 3, 2026UBSmainNeutralNeutral
Oct 27, 2026UBSmainNeutralNeutral
Oct 16, 2026JP MorganmainOverweightOverweight
Oct 12, 2026Keybancinit—Sector Weight
Aug 11, 2026BarclaysmainOverweightOverweight

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
idexx.com

News

Your note

Sign in to keep a note on IDXX — it syncs with the Stock Master app.

Insider holders

IDXX insider holders
InsiderRelationLatest transactionDateShares held
EMERSON ANDREWChief Financial OfficerConversion of Exercise of derivative securityAug 19, 20264,421
ERICKSON MICHAEL GOfficerConversion of Exercise of derivative securityFeb 18, 202615,092
FENNELL GEORGEOfficerConversion of Exercise of derivative securityMay 31, 202610,433
HUNT NIMRATA KOfficerSaleMar 2, 202618,300
KINGSLEY LAWRENCE DDirectorSaleSep 3, 20269,568
LANE MICHAEL JOfficerConversion of Exercise of derivative securityFeb 12, 20268,615

Institution ownership

IDXX institution ownership
Holder% heldSharesValueReported
Blackrock Inc.10.37%8,170,1785.71BJun 29, 2026
Vanguard Capital Management LLC6.54%5,152,2133.60BJun 29, 2026
Vanguard Portfolio Management LLC4.95%3,896,5212.72BJun 29, 2026
State Street Corporation4.76%3,748,6602.62BJun 29, 2026
Invesco Ltd.4.58%3,611,4162.52BJun 29, 2026
Geode Capital Management, LLC3.25%2,562,8861.79BJun 29, 2026

Fund ownership

IDXX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.18%2,504,3271.75BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%2,043,0871.43BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.17%1,709,2091.19BJun 29, 2026
Invesco QQQ Trust, Series 12.09%1,645,0671.15BSep 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%1,050,026733.50MSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%1,023,837715.20MSep 29, 2026